ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2021
Chromatin Remodeling of Colorectal Cancer Liver Metastasis is Mediated by an HGF-PU.1-DPP4 Axis.
Open access · goldAbstract read
In one paragraph
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 31 citations in OpenAlex.
- A magnetic resonance imaging-guided drug delivery system for premetastatic niche theranostics and colorectal cancer liver metastasis intervention.Journal of nanobiotechnology · 2026Article
- Perturbation of BRD4 and p300 activity suppresses super enhancer‑drivenOncology reports · 2026Article
- Methyltransferase MGMT upregulation drives metastasis by activating epithelial-mesenchymal transition in KRAS mutant colon cancer.Cell death & disease · 2026Article
- CRISPR Interference to Inhibit Oncogenes for Cancer Therapy.International journal of molecular sciences · 2026Review
- Identification and validation of DPP4 in predicting the prognosis of clear cell RCC.Discover oncology · 2026Article
- Construction and validation of a prognostic model associated with chromatin remodeling in hepatocellular carcinoma.Translational cancer research · 2026Article
- PU.1 aggravates hepatic sinusoidal obstruction syndrome by upregulating PTBP1 and activating the Wnt/β-catenin pathway.Histology and histopathology · 2026Article
- Review
- Understanding pre-metastatic niche formation: implications for colorectal cancer liver metastasis.Journal of translational medicine · 2025Review
- Enhancer reprogramming: critical roles in cancer and promising therapeutic strategies.Cell death discovery · 2025Review
- Precision scalpels for the epigenome: next-gen editing tools in targeted therapies.Frontiers in medicine · 2025Review
- Review
- Soluble CD26: From Suggested Biomarker for Cancer Diagnosis to Plausible Marker for Dynamic Monitoring of Immunotherapy.Cancers · 2024Review
- Peak Scores Significantly Depend on the Relationships between Contextual Signals in ChIP-Seq Peaks.International journal of molecular sciences · 2024Article
- A novel selenium analog of HDACi-based twin drug induces apoptosis and cell cycle arrest via CDC25A to improve prostate cancer therapy.Theranostics · 2024Article
- PU.1 induces tumor-associated macrophages promoting glioma progression through BTK-mediated Akt/mTOR pathway activation.American journal of cancer research · 2024Article
- The integrative multi-omics approach identifies the novel competing endogenous RNA (ceRNA) network in colorectal cancer.Scientific reports · 2023Article
- CRISPR/dCas9 Tools: Epigenetic Mechanism and Application in Gene Transcriptional Regulation.International journal of molecular sciences · 2023Review
- Article
- Intracellular and extracellular factors of colorectal cancer liver metastasis: a pivotal perplex to be fully elucidated.Cancer cell international · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 5 institutions in 3 countries.
Lihua WangDepartment of Biomedical Engineering, Duke University, Durham, NC, 27708, USA.
Ergang WangDepartment of Biomedical Engineering, Duke University, Durham, NC, 27708, USA.
Jorge Prado BalcazarDepartment of Biomedical Engineering, Duke University, Durham, NC, 27708, USA.
Zhenzhen WuKey Laboratory of RNA Biology, Key Laboratory of Protein and Peptide Pharmaceutical, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China.
Kun XiangDepartment of Biomedical Engineering, Duke University, Durham, NC, 27708, USA.
Yi WangDepartment of Biomedical Engineering, Duke University, Durham, NC, 27708, USA.
Qiang HuangDepartment of Biomedical Engineering, Duke University, Durham, NC, 27708, USA.
Marcos NegreteDepartment of Biomedical Engineering, Duke University, Durham, NC, 27708, USA.
Kai-Yuan ChenDepartment of Biomedical Engineering, Duke University, Durham, NC, 27708, USA.
Wei LiDepartment of Biomedical Engineering, Duke University, Durham, NC, 27708, USA.
Yujie FuDepartment of Biomedical Engineering, Duke University, Durham, NC, 27708, USA.
Anders DohlmanDepartment of Biomedical Engineering, Duke University, Durham, NC, 27708, USA.
Robert MinesDepartment of Biomedical Engineering, Duke University, Durham, NC, 27708, USA.
Liwen ZhangKey Laboratory of RNA Biology, Key Laboratory of Protein and Peptide Pharmaceutical, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China.
Yoshihiko KobayashiDepartment of Cell Biology, Regeneration Next, Duke University School of Medicine, Durham, NC, 27710, USA.
Tianyi ChenDepartment of Biomedical Engineering, Duke University, Durham, NC, 27708, USA.
Guizhi ShiLaboratory Animal Research Center, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China.
John Paul ShenDepartment of Gastrointestinal Medical Oncology, MD Anderson, Durham, NC, 77030, USA.
Scott KopetzDepartment of Gastrointestinal Medical Oncology, MD Anderson, Durham, NC, 77030, USA.
Purushothama Rao TataDepartment of Cell Biology, Regeneration Next, Duke University School of Medicine, Durham, NC, 27710, USA.
Victor MorenoDepartment of Clinical Sciences, University of Barcelona, Barcelona, 08193, Spain.
Charles GersbachDepartment of Biomedical Engineering, Duke University, Durham, NC, 27708, USA.
Gregory CrawfordDepartment of Pediatrics, Duke University School of Medicine, Durham, NC, 27710, USA.
David HsuDepartment of Medicine, Duke University School of Medicine, Durham, NC, 27710, USA.
Emina HuangDepartment of Cancer Biology and Colorectal Surgery, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, 44195, USA.
Pengcheng BuKey Laboratory of RNA Biology, Key Laboratory of Protein and Peptide Pharmaceutical, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China.
Xiling ShenDepartment of Biomedical Engineering, Duke University, Durham, NC, 27708, USA.ORCID 0000-0002-4978-3531
Duke University · USChinese Academy of Sciences · CNAnderson University - South Carolina · USCleveland Clinic Lerner College of Medicine · USInstitut d'Investigació Biomédica de Bellvitge · ES
Funding
Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI JOHN N. NORTON · 1985 to 2026
$174.8MAn organotypic model recapitulating colon cancer microenvironment and metastasisU01CA214300 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HUANG, EMINA HUI-NA, SHEN, XILING · 2017 to 2021
$3.1MEpigenomic Reprogramming in Patient Derived Models of Colorectal CancerU01CA217514 · NCI · DUKE UNIVERSITY · PI HSU, SHIAOWEN DAVID · 2018 to 2022
$3.1MThe miR-20/c-Myc/E2F Regulatory Axis is Critical for the Tumor Promoting Activity of Inflammatory Fibroblasts in Colitis-Associated CancerR01CA237304 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HUANG, EMINA HUI-NA, WESSELY, OLIVER · 2019 to 2023
$2.9MHigh-Throughput Functional Genomics to Guide Precision Oncology in Gastrointestinal TumorsK22CA234406 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SHEN, JOHN PAUL YING CHING · 2019 to 2021
$577kChinese Ministry of Science and Technology 2017YFA0504103National Natural Science Foundation of China 31771513National Natural Science Foundation of China 81921003National Natural Science Foundation of China 81972797NCI NIH HHS K22 CA234406NCI NIH HHS P30 CA014236NCI NIH HHS R01 CA237304NCI NIH HHS U01 CA214300NCI NIH HHS U01 CA217514NIH HHS P30-CA014236-44NIH HHS R01 CA237304NIH HHS U01-CA214300NIH HHS U01-CA217514Strategic Priority Research Program of the Chinese Academy of Science XDB29040100
Abstract
Colorectal cancer (CRC) metastasizes mainly to the liver, which accounts for the majority of CRC-related deaths. Here it is shown that metastatic cells undergo specific chromatin remodeling in the liver. Hepatic growth factor (HGF) induces phosphorylation of PU.1, a pioneer factor, which in turn binds and opens chromatin regions of downstream effector genes. PU.1 increases histone acetylation at the DPP4 locus. Precise epigenetic silencing by CRISPR/dCas9
Indexed as
AnimalsChromatin Assembly and DisassemblyColorectal NeoplasmsDipeptidyl Peptidase 4Epigenesis, GeneticGene Expression Regulation, NeoplasticHepatocyte Growth FactorHumansLiver NeoplasmsMiceMice, Inbred BALB CPromoter Regions, GeneticProto-Oncogene ProteinsProto-Oncogene Protein Spi-1Trans-ActivatorsDipeptidyl Peptidase 4Hepatocyte Growth FactorHGF protein, humanProto-Oncogene ProteinsProto-Oncogene Protein Spi-1Trans-Activatorschromatin remodelingcolorectal cancerDPP4epigeneticshepatic growth factor (HGF)metastasisPU.1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.